Search results for " chronic obstructive"

showing 10 items of 295 documents

CAT score single item analysis in patients with COPD: results from COSYCONET

2019

Abstract The COPD Assessment Test (CAT) is in widespread use for the evaluation of patients with chronic obstructive pulmonary disease (COPD). We assessed whether the CAT items carry additional information beyond the sum score regarding COPD characteristics including emphysema. Patients of GOLD grades 1 to 4 from the COPD cohort COSYCONET (German COPD and Systemic Consequences - Comorbidities Network) with complete CAT data were included (n = 2270), of whom 493 had chest CT evaluated for the presence of emphysema. Comorbidities and lung function were assessed following standardised procedures. Cross-sectional data analysis was based on multiple regression analysis of the single CAT items ag…

Pulmonary and Respiratory MedicinePercentilemedicine.medical_specialtyMedizinDiagnostic Techniques Respiratory System610Single itemCAT score03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicinemedicineCOPDIn patient030212 general & internal medicineLung functionEmphysemaCOPDbusiness.industryRegression analysisCat Score ; Copd ; Emphysemamedicine.diseaseExploratory factor analysisrespiratory tract diseases030228 respiratory systemCohortbusiness61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
researchProduct

Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution

2022

Although bronchodilators are the cornerstone in chronic obstructive pulmonary disease (COPD) therapy, the treatment with a single-agent bronchodilator may not provide adequate symptoms control in COPD. The combination of drugs with different mechanisms of action may be more effective in inducing bronchodilation and preventing exacerbations, with a lower risk of side-effects in comparison with the increase of the dose of a single molecule. Several studies comparing the triple therapy with the association of long-acting ß2 agonist (LABA)/inhaled corticosteroid (ICS) or long-acting muscarinic antagonist (LAMA)/LABA reported improvement of lung function and quality of life. A significant reduc…

Pulmonary and Respiratory MedicineRC705-779ReviewMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioCOPD inhaled extrafine formulation triple therapyinhaled extrafine formulationBronchodilator AgentsDrug CombinationsPulmonary Disease Chronic ObstructiveDiseases of the respiratory systemtriple therapyFormoterol FumarateAdministration InhalationQuality of LifeCOPDHumansDrug Therapy CombinationPharmacology (medical)Adrenergic beta-2 Receptor AgonistsTherapeutic Advances in Respiratory Disease
researchProduct

Do Saharan Dust Days Carry a Risk of Hospitalization From Respiratory Diseases for Citizens of the Canary Islands (Spain)?

2021

Background: Saharan dust meets the Canary Islands at the beginning of its westward path across the North Atlantic, exceeding the European daily levels for PM10; for this reason, their two provincial capital cities, constitute optimal sites where to evaluate the health effects of this natural event. Objectives: To assess the short-term association between Saharan Dust Days (SDDs) and respiratory morbidity in the two capital cities. Methods: We carried out a time-series analysis with daily emergency hospital admissions due to all respiratory system diseases, chronic obstructive pulmonary disease (COPD) and asthma between 2001 and 2005, assessing the independent effect of SDDs, defined accordi…

Pulmonary and Respiratory MedicineSeries temporalesRespiratory diseasesSaharan dustProvincial capitalGeneralized additive modelPulmonary diseaseCalima saharianaMineral dustIngresos hospitalariosPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineAir PollutionEnvironmental healthRespiratory morbiditymedicineHumansAfrican air intrusionsRespiratory systemAsthmaHospital admissionsAir PollutantsCOPDbusiness.industryDustGeneral MedicineIntrusiones de aire africanoRespiration Disordersmedicine.diseaseModelos aditivos generalizadosAsthmaConfidence intervalPartículas en suspensiónHospitalizationEnfermedades respiratorias030228 respiratory systemSpainParticulate MatterTime-seriesbusinessParticulate matter
researchProduct

Short-term benefit of smoking cessation along with glycopirronium on lung function and respiratory symptoms in mild COPD patients: a retrospective st…

2018

Introduction. Tobacco smoke is the leading cause of chronic obstructive pulmonary disease (COPD). Smoking cessation can change the natural history of COPD, as we know from the GOLD guidelines. Little is known about the short-term clinical and functional effects of smoking cessation treatment combined with anti-muscarinic bronchodilators. Objective. To determine whether quitting smoking, obtained by smoking cessation treatment combined with the use of a new long-acting muscarinic antagonist bronchodilator (LAMA), can improve lung function tests and respiratory symptoms more than the use of LAMA alone. Methods. We evaluated, in a retrospective analysis, the functional and clinical data, colle…

Pulmonary and Respiratory MedicineSpirometryAdultMalemedicine.medical_specialtyTime Factorsmedicine.drug_classmedicine.medical_treatmentMuscarinic AntagonistsTobacco smokePulmonary function testing03 medical and health scienceschemistry.chemical_compoundPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicineBronchodilatorMedicineHumans030212 general & internal medicineVareniclineLungAgedRetrospective StudiesCOPDmedicine.diagnostic_testbusiness.industryRespirationRetrospective cohort studymedicine.diseaseRespiratory Function Tests030228 respiratory systemchemistrySmoking cessationMandelic AcidsRegression AnalysisFemaleSmoking CessationbusinessJournal of breath research
researchProduct

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

2011

Two, once daily (q.d.) inhaled bronchodilators are available for the treatment of chronic obstructive pulmonary disease (COPD): the β(2)-agonist indacaterol and the anticholinergic tiotropium. This blinded study compared the efficacy of these two agents and assessed their safety and tolerability. Patients with moderate-to-severe COPD were randomised to treatment with indacaterol 150 μg q.d. (n=797) or tiotropium 18 μg q.d. (n=801) for 12 weeks. After 12 weeks, the two treatments had similar overall effects on "trough" (24 h post-dose) forced expiratory volume in 1 s. Indacaterol-treated patients had greater improvements in transition dyspnoea index (TDI) total score (least squares means 2.0…

Pulmonary and Respiratory MedicineSpirometryMalemedicine.drug_classScopolamine DerivativesQuinolonesSeverity of Illness IndexCholinergic AntagonistsDrug Administration ScheduleMedical Recordslaw.inventionPulmonary Disease Chronic ObstructiveRandomized controlled trialDouble-Blind MethodlawAdrenergic beta-2 Receptor AntagonistsForced Expiratory VolumemedicineAnticholinergicHumansTiotropium BromideAdverse effectAgedCOPDmedicine.diagnostic_testbusiness.industryTiotropium bromideMiddle Agedmedicine.diseaserespiratory tract diseasesBronchodilator AgentsTreatment OutcomeTolerabilitySpirometryAnesthesiaIndansIndacaterolFemalebusinessmedicine.drugThe European respiratory journal
researchProduct

Alternative ways of expressing FEV1 and mortality in elderly people with and without COPD

2013

Expressing forced expiratory volume in 1 s (FEV1) as % predicted relies on the assumption of proportional variability and generalisability of prediction equations that may be unrealistic, especially for elderly people. We evaluated the prognostic implications of alternative ways of expressing FEV1. We enrolled 318 patients with chronic obstructive pulmonary disease (COPD) and 475 controls in the Salute Respiratoria nell'Anziano (SARA) study. The risk for 5-, 10- and 15-year mortality associated with FEV1 was studied by expressing FEV1 % pred, standardised by height cubed (FEV1 · Ht(-3)) and as a multiple of the sex-specific first percentile (FEV1 quotient (FEV1Q)). In the group with COPD, t…

Pulmonary and Respiratory MedicineSpirometryMalemedicine.medical_specialtyPediatricsPercentilePrognosiPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioRate ratioPulmonary Disease Chronic ObstructiveElderly populationInternal medicineForced Expiratory VolumeHumansMedicineElderly peopleRespiratory Function TestAgedCOPDmedicine.diagnostic_testbusiness.industryRespiratory Function Tests; Spirometry; Humans; Treatment Outcome; Prognosis; Case-Control Studies; Aged; Middle Aged; Forced Expiratory Volume; Male; Female; Pulmonary Disease Chronic ObstructiveCase-control studyrespiratory systemMiddle AgedPrognosismedicine.diseaseRespiratory Function Testsrespiratory tract diseasesTreatment OutcomeSpirometryCase-Control StudiesFemalebusinessCase-Control StudieHuman
researchProduct

Why chronic obstructive pulmonary disease patients get so short of breath with limited activity

2013

equivalence despite the simplicity of MPT versus CPET as a surrogate to detect DH in COPD patients, by measuring the decrease in inspiratory capacity to reflect the increase in end-expiratory lung volume [3] . Lahaije et al. [2] have investigated whether DH as measured in the laboratory settings (CPET and MPT) reflects DH that is associated with dyspnea-limiting ADL. The authors conclude that both CPET and MPT can serve as a screening tool to identify patients who are susceptible to develop DH during ADL. In practice, MPT is simpler to obtain and is an inexpensive surrogate. However, sensitivity of MPT may not be optimal. When DH does not occur during CPET, it is unlikely to occur during AD…

Pulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtyWeaknessSettore MED/10 - Malattie Dell'Apparato RespiratorioTachypneaPulmonary Disease Chronic ObstructiveActivities of Daily LivingmedicineHumansLung volumesIntensive care medicineDynamic hyperinflationCOPDLungmedicine.diagnostic_testbusiness.industryAirway obstructionmedicine.diseaserespiratory tract diseasesmedicine.anatomical_structureExercise Testmedicine.symptombusinessExercise Test; Humans; Activities of Daily Living; Pulmonary Disease Chronic ObstructiveHuman
researchProduct

Inhaler mishandling remains common in real life and is associated with reduced disease control

2011

SummaryProper inhaler technique is crucial for effective management of asthma and COPD. This multicentre, cross-sectional, observational study investigates the prevalence of inhaler mishandling in a large population of experienced patients referring to chest clinics; to analyze the variables associated with misuse and the relationship between inhaler handling and health-care resources use and disease control.We enrolled 1664 adult subjects (mean age 62 years) affected mostly by COPD (52%) and asthma (42%). Respectively, 843 and 1113 patients were using MDIs and DPIs at home; of the latter, the users of Aerolizer®, Diskus®, HandiHaler® and Turbuhaler® were 82, 467, 505 and 361.We have a tota…

Pulmonary and Respiratory MedicineVital capacitymedicine.medical_specialtyCross-sectional studyPopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioMDIPulmonary Disease Chronic ObstructiveFEV1/FVC ratioPatient Education as TopicAdministration InhalationInhaler techniquemedicineCOPDHumansMetered Dose InhalerseducationAsthmaCOPDeducation.field_of_studybusiness.industryInhalerPatient educationMiddle Agedmedicine.diseaseAsthmaDry-powder inhalerasthma therapy deviceDPISelf CareCross-Sectional StudiesEmergency medicinePhysical therapyPatient ComplianceFemalebusinessRespiratory Medicine
researchProduct

Circulating CD34+ cells are decreased in chronic obstructive pulmonary disease.

2006

Pulmonary and Respiratory Medicineaged; antigens; biological markers; blood; blood/immunology; cd34; chronic obstructive; humans; pulmonary disease; severity of illness indexchronic obstructivebusiness.industryCd34 cellsPulmonary diseaseAntigens CD34cd34Severity of Illness IndexPulmonary Disease Chronic ObstructiveText miningantigensbloodImmunologyMedicineHumansblood/immunologybusinessbiological markersBiomarkerspulmonary diseaseAgedProceedings of the American Thoracic Society
researchProduct

A simple noninvasive pressure–time index at the mouth to measure respiratory load during acute exacerbation of COPD A comparison with normal voluntee…

2003

We assessed the validity of the pressure-time index (PTI) measured at the mouth as a noninvasive and simplified alternative to conventional tension-time index for assessing respiratory load and inspiratory muscle force reserve. PTI was measured within 48 h of hospital admission and at 24 h before discharge in 37 consecutive patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) using the equation PTI = (P(awo)/MIP)(T(I)/T(T)) 100, where P(awo) is the mean airway pressure measured at the mouth, MIP the maximal inspiratory pressure, and T(I)/T(T) the inspiratory time (T(I)) to total cycle length (T(T)) ratio. Controls were 30 normal volunteers with similar anthropome…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyAcute exacerbation of chronic obstructive pulmonary diseaseTime FactorsExacerbationPartial PressureVital CapacityPopulationMean airway pressurechronic obstructive pulmonary diseasePulmonary Disease Chronic ObstructiveForced Expiratory VolumeInternal medicinePressureRespiratory musclemedicineHumansRespiratory systemeducationAgedWork of Breathingeducation.field_of_studyCOPDbusiness.industryRespirationRespiratory diseaseCarbon Dioxidemedicine.diseaseRespiratory MusclesSurgeryOxygenrespiratory muscle fatiguerespiratory loadCardiologyFeasibility StudiesBlood Gas Analysispressure–time indexbusinessRespiratory Medicine
researchProduct